Abstract:BackgroundTislelizumab, an anti-programmed cell death protein-1 monoclonal antibody, demonstrated clinical activity and was well tolerated in patients with previously treated advanced HCC in the open-label, multicenter, Phase 2 RATIONALE-208 study (NCT03419897). We report exploratory analysis of the association of gene expression profiles (GEPs) with response to tislelizumab in patients with previously treated advanced HCC.MethodsEligible patients who had received ≥1 prior line of systemic therapy for advanced HCC received tislelizumab (200 mg) intravenously once every 3 weeks and tumor response was evaluated per RECIST v.1.1. Baseline tumor sampling was optional and GEP analysis was performed using HTG EdgeSeq Precision Immuno-Oncology panel in 138 tumor samples (fresh tumor, n=6; archival tumor, n=132). Signature scores were calculated using Gene Set Variation Analysis package with publicly available gene signatures (GS). GS or genes differentially expressed between responders and non-responders (NRs) were determined using Wilcoxon rank-sum test and modified t-test with limma. Distributions of overall survival (OS) and progression-free survival (PFS) for GS subgroups (high vs low) were estimated by Kaplan-Meier method. Hierarchical clustering of NRs was achieved using 1-Pearson’s correlation and average linkage. All statistical analysis results are post-hoc exploratory and thereby p values are descriptive.Results249 patients were enrolled and received ≥1 dose of tislelizumab; 138 patients had evaluable GEP data, of which 132 patients had evaluable GEP and tumor response data. GEP analysis demonstrated that CD4 T cell, CD8 T cell, cytotoxic T lymphocyte and major histocompatibility complex class I signatures were enriched in responders, and cancer-associated fibroblasts, angiogenesis and hypoxia signatures were enriched in NRs (figure 1). CD8B_PDCD1_9, a novel GS identified, comprises 9 genes highly expressed in responders: CD8B, CXCL13, KLRD1, NKG7, HLA-A, HLA-G, LAG3, PDCD1 and KREMEN1. Higher objective response rate (ORR; p<0.0001, by Fisher’s exact test) and longer PFS (p=0.005, by log rank test) were observed in patients with high vs low CD8B_PDCD1_9 score (ORR: 26% vs 3%; median PFS: 2.8 months vs 1.8 months). To explore the heterogeneity of molecular features in NRs, NRs were clustered into 3 subgroups using a series of tumor-immune GS. OS and PFS for the 3 NR subgroups with distinct GS are summarized in table 1.Abstact 360 Figure 1Correlation between GS and ORR in patients with previously treated advanced HCC treated with tislelizumab monotherapyAbstact 360 Table 1OS and PFS of NR subgroupsCl, confidence interval; NE, not evaluable; GS, gene signature; NR, non-responder; OS, overall survival; PFS, progression-free survivalConclusionsThis exploratory analysis identified distinct GS associated with tumor response and resistance to tislelizumab monotherapy in patients with previously treated advanced HCC and increases our understanding of the tumor microenvironment. Further GEP analyses will be undertaken in an on-going Phase 3 study (NCT03412773).AcknowledgementsThis study is sponsored by BeiGene Ltd. Medical writing support for the development of this abstract, under direction of the authors, was provided by Claire White, PhD, of Ashfield MedComms, an Ashfield Health company, and was funded by BeiGene Ltd.Trial RegistrationNCT03419897Ethics ApprovalThis study was conducted according to the ethical principles of the Declaration of Helsinki, Good Clinical Practice guidelines, the principles of informed consent and the requirements of the public registration of clinical trials. Written informed consent was obtained from each patient prior to screening. The protocol was approved by the institutional ethics committee and was monitored by a safety monitoring committee.

936P Effects of Tislelizumab (TIS) Monotherapy on Health-Related Quality of Life in Patients with Previously Treated Unresectable Hepatocellular Carcinoma (HCC)

1057P Long-term Follow-Up of a Phase II Study of Tislelizumab (TIS) Monotherapy in Patients (pts) with Previously Treated, Locally Advanced, Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dmmr) Solid Tumors

P17.02 RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo Vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC

O-1 Results from a Global Phase 2 Study of Tislelizumab, an Investigational PD-1 Antibody, in Patients with Unresectable Hepatocellular Carcinoma

Efficacy, Safety, and Pharmacokinetics of the Anti-Programmed Cell Death Receptor-1 (PD-1) Monoclonal Antibody, Tislelizumab (BGB-A317) in a Phase 2, Open-Label, Multicenter Study to Investigate in Patients with Unresectable Hepatocellular Carcinoma - Trial in Progress

360 Tumor-immune Signatures Associated with Response or Resistance to Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC)

Effect of Human Hydrosalpinx Fluid on in Vitro Mouse Embryogenesis.

Abstract CT552: RATIONALE 304: Tislelizumab (TIS) Plus Chemotherapy Versus Chemotherapy Alone As First-Line (1L) Treatment for Non-Squamous (Non-Sq) NSCLC in Patients (pts) Aged 65-75 Years

P-25 Tislelizumab Monotherapy for Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC): RATIONALE-208 Chinese Subpopulation

Clinical Outcomes Associated with Tislelizumab in Patients (pts) with Advanced Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib (SOR) or Lenvatinib (LEN) in RATIONALE-208.

1263P Tislelizumab + Chemotherapy Vs Chemotherapy Alone As First-Line Treatment for Locally Advanced/metastatic Nonsquamous NSCLC

Clinical Outcomes in Patients (pts) with Previously Treated Advanced Hepatocellular Carcinoma (HCC) Experiencing Hepatitis B Virus (HBV) DNA Increases During Tislelizumab (TIS) Treatment in RATIONALE-208

Tislelizumab Versus Chemotherapy As Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC, RATIONALE 302): Impact on Health-Related Quality of Life (Hrqol)

P2.04-29 Preliminary Results with Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

Tislelizumab vs sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 study

Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.

Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).

Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial

Effects of tislelizumab on health‐related quality of life in patients with recurrent or metastatic nasopharyngeal cancer

LBA36 Final Analysis of RATIONALE-301: Randomized, Phase III Study of Tislelizumab Versus Sorafenib As First-Line Treatment for Unresectable Hepatocellular Carcinoma

Tislelizumab in Combination with Chemotherapy for the Treatment of Chinese Patients (pts) with Esophageal Squamous Cell Carcinoma (ESCC): Results from One Cohort of an Ongoing Phase 2 Study.